Sildenafil for Treatment of Choroidal Ischemia

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 11, 2014

Primary Completion Date

February 18, 2020

Study Completion Date

February 18, 2020

Conditions
Choroidal IschemiaVitelliform Macular DystrophyAge-related Macular DegenerationCentral Serous RetinopathyRetinitis Pigmentosa
Interventions
DRUG

Sildenafil

Initial Sildenafil dosage will be weight dependent. Participants will start at 40 mg daily (20mg in the morning, 20 mg in the evening) or 60 mg daily (40mg in the morning and 20 mg in the evening). Sildenafil dosage may be increased to up to 80mg daily (20-40mg in the morning and 20-40mg in the evening) based on the response to lower doses. If the participant has not had improvement after initial treatment, the dose may be increased, at the discretion of the study physician.

OTHER

Standard of Care Sildenafil

Medical record review of participants that receive Sildenafil as part of standard of care.

DIAGNOSTIC_TEST

Ocular Coherence Tomography-Angiography (OCT-A)

Retinal photographs will be taken at each study visit.

OTHER

Visual Acuity (VA)

Visual acuity will be measured with Snellen Eye Chart at each study visit.

Trial Locations (1)

10032

Columbia University Medical Center, Edward Harkness Eye Institute, New York

All Listed Sponsors
lead

Columbia University

OTHER

NCT04356716 - Sildenafil for Treatment of Choroidal Ischemia | Biotech Hunter | Biotech Hunter